Acute Myeloid Leukemia AML Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

Acute Myeloid Leukemia (AML) Market is segmented By Therapy (Chemotherapy, Targeted Therapy, Immunotherapy), By Route of Administration (Oral, Intravenous), By End User (Hospitals, Specialty Clinics), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned segments.

Acute Myeloid Leukemia (AML) Market is segmented By Therapy (Chemotherapy, Targeted Therapy, Immunotherapy), By Route of Administration (Oral, Intrave....

Acute Myeloid Leukemia AML Market Size

Market Size in USD

CAGR7.5%

Study Period	2024 - 2031
Base Year of Estimation	2023
CAGR	7.5%
Market Concentration	Medium
Major Players	Bristol-Myers Squibb, AbbVie, Pfizer, F. Hoffmann-La Roche, Novartis

*Disclaimer: Major players are listed in no particular order.

*Source: Coherent Market Insights

Want to purchase customized report?
please let us know !

Acute Myeloid Leukemia AML Market Analysis

The Acute Myeloid Leukemia (AML) market is estimated to be valued at USD 1.613 billion in 2024 and is expected to reach USD 2.68 billion by 2031, growing at a compound annual growth rate (CAGR) of 7.5% from 2024 to 2031.

The growing geriatric population who are susceptible to develop AML combined with the rising demand for targeted drug therapy for better treatment outcomes are key factors expected to drive the growth of the AML market.

Acute Myeloid Leukemia AML Market Report Snapshots

Buy Now